Mr Andrew Sinclair

KANDO id: 33122

Bio

Has more than eight years experience as an analyst in the pharmaceutical and biotechnology sectors. Joined Abingworth in 2008 from HSBC Global Markets and was Senior Equity Analyst, Director, responsible for investment research in the mid-cap pharmaceutical sector. Previously, held biotechnology analyst positions at Credit Suisse and SG Cowen. At Abingworth, evaluates opportunities in public companies and is a Fund Manager for open market transactions. PhD in Chemistry and Genetic Engineering at the BBSRC Institute of Plant Science, Norwich, and holds a BSc in Microbiology from King’s College London. Qualified as a Chartered Accountant with KPMG.

Career


Abingworth LLP

An international investment group dedicated exclusively to the life sciences and healthcare sectors

Education